Introduction and Objective: Despite the proven benefits of CGM, adoption in primary care remains limited. We present the results of a system-wide CGM education and implementation program at a large academic institution. Methods: The program was implemented across 34 primary care clinics from February 2023 to February 2026. It combined in-person and virtual conferences with clinic-based training for residents, faculty, nursing staff, and support staff on CGM placement, with a focus on ordering, data interpretation, and workflow integration. Participants completed anonymous pre- and post-survey assessments of satisfaction, knowledge, confidence, and perceived barriers. Annual CGM orders and changes in HbA1c from baseline and at 3, 6, 9, and 12 months of CGM use were analyzed. Results: A total of 1,313 healthcare professionals completed training (52% in-person or virtual conference-based, and 48% clinic-based sessions). Satisfaction was rated excellent (57.8%) or good (29.9%). Pre-post training Likert results showed significant improvement in CGM placement competency (63.6% to 93.1%), knowledge of benefits and limitations (64.8% to 93.3%), ordering expertise (51.4% to 78.6%), device connectivity confidence (59.5% to 90.0%), and data platform integration (49% to 75%) (all p0.0001). Overall, 20,724 CGM devices were ordered, with annual complete orders increasing from 804 in 2022 to 7,603 in 2025, representing a ninefold increase during the implementation period. Mean HbA1c decreased by 0.38% at 3 months, 0.52% at 6 months, and 0.55% at 12 months. Major barriers identified included insurance coverage, limited support staff, and software integration challenges. Conclusion: A structured, scalable CGM education strategy in primary care significantly improved provider competency, substantially increased CGM utilization, and improved glycemic control. Despite ongoing insurance and workflow barriers, this scalable model effectively expanded CGM use and improved diabetes outcomes in primary care. Disclosure I.C. Flores Shih: None. S. Jairam: None. B. Marshall: None. S.L. Kantipudi: None. R. Celedon: None. G. Arribas: None. S. Sharma: None. V.S. Diaz-Sarmiento: None. G. Umpierrez: Research Support; Current; Abbott, Dexcom, Inc., Bayer AG. Advisory Panel; Ended; Sanofi-Aventis U.S., Dexcom, Inc. Other - Education grant; Current; Lilly Diabetes, Abbott Diabetes. Advisory Panel; Current; Glycare, Glucotrack. Research Support; Current; Corcept Therapeutics. Funding Abbott Diabetes Care (0000071762)
Shih et al. (Fri,) studied this question.